<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cns70444" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CNS Neurosci Ther</journal-id><journal-id journal-id-type="iso-abbrev">CNS Neurosci Ther</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1755-5949</journal-id><journal-id journal-id-type="publisher-id">CNS</journal-id><journal-title-group><journal-title>CNS Neuroscience &#x00026; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">1755-5930</issn><issn pub-type="epub">1755-5949</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40406905</article-id><article-id pub-id-type="pmc">PMC12099309</article-id><article-id pub-id-type="doi">10.1111/cns.70444</article-id><article-id pub-id-type="publisher-id">CNS70444</article-id><article-id pub-id-type="other">CNSNT-2024-2626.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Poly&#x02010;<styled-content style="fixed-case" toggle="no">IC</styled-content> Alleviates Nitroglycerin&#x02010;Induced Migraine by Inhibiting Neuroinflammation via <styled-content style="fixed-case" toggle="no">TLR3</styled-content>/<styled-content style="fixed-case" toggle="no">TRIF</styled-content> Signaling Pathway</article-title></title-group><contrib-group><contrib id="cns70444-cr-0001" contrib-type="author"><name><surname>Hong</surname><given-names>Ye</given-names></name><xref rid="cns70444-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cns70444-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cns70444-cr-0002" contrib-type="author"><name><surname>Ma</surname><given-names>Mengmeng</given-names></name><xref rid="cns70444-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cns70444-cr-0003" contrib-type="author"><name><surname>Li</surname><given-names>Changling</given-names></name><xref rid="cns70444-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cns70444-cr-0004" contrib-type="author"><name><surname>Zhang</surname><given-names>Yang</given-names></name><xref rid="cns70444-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cns70444-cr-0005" contrib-type="author"><name><surname>Li</surname><given-names>Yanbo</given-names></name><xref rid="cns70444-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cns70444-cr-0006" contrib-type="author"><name><surname>Chen</surname><given-names>Ning</given-names></name><xref rid="cns70444-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cns70444-cr-0007" contrib-type="author" corresp="yes"><name><surname>Fang</surname><given-names>Jinghuan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2553-9139</contrib-id><xref rid="cns70444-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>jinghuan_fang@126.com</email></address></contrib><contrib id="cns70444-cr-0008" contrib-type="author" corresp="yes"><name><surname>He</surname><given-names>Li</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2034-1027</contrib-id><xref rid="cns70444-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>heli2003new@126.com</email></address></contrib></contrib-group><aff id="cns70444-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>West China Hospital of Sichuan University</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="cns70444-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>The Third Affiliated Hospital of Sun Yat&#x02010;Sen University</institution>
<city>Guangzhou</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Jinghuan Fang (<email>jinghuan_fang@126.com</email>)<break/>
Li He (<email>heli2003new@126.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>31</volume><issue seq="460">5</issue><issue-id pub-id-type="doi">10.1111/cns.v31.5</issue-id><elocation-id>e70444</elocation-id><history>
<date date-type="rev-recd"><day>18</day><month>4</month><year>2025</year></date>
<date date-type="received"><day>05</day><month>12</month><year>2024</year></date>
<date date-type="accepted"><day>06</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">CNS Neuroscience &#x00026; Therapeutics</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CNS-31-e70444.pdf"/><abstract><title>ABSTRACT</title><sec id="cns70444-sec-0001"><title>Aims</title><p>Toll&#x02010;like receptors (TLRs) play critical roles in pain modulation and immune responses. Polyinosinic&#x02010;polycytidylic acid (Poly&#x02010;IC), a TLR3&#x02010;specific ligand, has shown promise in exerting neuroprotective effects, as it mitigates inflammation in several diseases. Considering that sterile neurogenic inflammation is involved in the pathogenesis of migraine, we explored the impact of Poly&#x02010;IC on episodic migraine treatment and the potential mechanisms involved.</p></sec><sec id="cns70444-sec-0002"><title>Methods</title><p>Episodic migraine was induced in male rats via a single intraperitoneal injection of nitroglycerin. Poly&#x02010;IC (with or without a TLR3 inhibitor) treatment was performed before migraine induction. Pain was assessed according to the mechanical sensitivity threshold, head&#x02010;directed grooming, and the Rat Grimace Scale. The expression of TLR3 and its downstream molecule TRIF was subsequently examined, after which calcitonin gene&#x02010;related peptide (CGRP), c&#x02010;fos, and proinflammatory cytokine expression was assessed. Moreover, TRIF expression in primary cultured neurons was knocked down by shRNA in&#x000a0;vitro to further explore the mechanisms by which Poly&#x02010;IC mediates migraine&#x02010;like inflammation.</p></sec><sec id="cns70444-sec-0003"><title>Results</title><p>Poly&#x02010;IC treatment significantly upregulated TLR3/TRIF expression, reduced the production of CGRP, c&#x02010;fos, and inflammatory cytokines, and alleviated allodynia in an animal model of migraine. Moreover, TRIF knockdown blunted the anti&#x02010;inflammatory effects of Poly&#x02010;IC treatment in primary cultured neurons.</p></sec><sec id="cns70444-sec-0004"><title>Conclusions</title><p>Poly&#x02010;IC exerts therapeutic effects against neurogenic inflammation via the TLR3/TRIF signaling pathway in an episodic migraine model.</p></sec></abstract><abstract abstract-type="graphical"><p>A promising new drug target for the migraine treatment: Poly&#x02010;IC delivery can activate TLR3/TRIF signaling pathway and exert protective effects by blocking pro&#x02010;inflammatory responses in migraine.<boxed-text position="anchor" content-type="graphic" id="cns70444-blkfxd-0001"><graphic xlink:href="CNS-31-e70444-g008.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cns70444-kwd-0001">migraine</kwd><kwd id="cns70444-kwd-0002">neuroinflammation</kwd><kwd id="cns70444-kwd-0003">neurons</kwd><kwd id="cns70444-kwd-0004">poly&#x02010;IC</kwd><kwd id="cns70444-kwd-0005">TLR3/TRIF signaling way</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82301404</award-id><award-id>82271360</award-id><award-id>82101395</award-id></award-group><award-group id="funding-0002"><funding-source>China Postdoctoral Science Foundation funded project</funding-source><award-id>2021M692294</award-id></award-group></funding-group><counts><fig-count count="8"/><table-count count="0"/><page-count count="13"/><word-count count="7100"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cns70444-ntgp-0001"><fn fn-type="funding" id="cns70444-note-0001"><p>
<bold>Funding:</bold> This project was supported by the National Natural Science Foundation of China (Grant 82301404, 82271360, and 82101395), China Postdoctoral Science Foundation funded project (No. 2021M692294).</p></fn><fn fn-type="equal" id="cns70444-note-0002"><p>Ye Hong and Mengmeng Ma contributed equally to the manuscript as first authors.</p></fn></fn-group></notes></front><body id="cns70444-body-0001"><sec id="cns70444-sec-0005"><label>1</label><title>Introduction</title><p>Migraine is a common and debilitating neurological disorder characterized by recurring and unpredictable episodic attacks of intense head pain that affects 15% of the population worldwide [<xref rid="cns70444-bib-0001" ref-type="bibr">1</xref>, <xref rid="cns70444-bib-0002" ref-type="bibr">2</xref>]. However, the current therapeutic strategies are not completely effective due to the limited options available [<xref rid="cns70444-bib-0003" ref-type="bibr">3</xref>]. Moreover, poor treatment efficacy is observed among individuals with episodic migraine; this leads to longer periods of exposure to pain and increases the risk of disabling chronic migraine, which causes a considerable economic burden to society [<xref rid="cns70444-bib-0004" ref-type="bibr">4</xref>, <xref rid="cns70444-bib-0005" ref-type="bibr">5</xref>]. Consequently, novel treatment options for migraine are urgently needed.</p><p>A series of studies has suggested that sterile neurogenic inflammation is involved in the pathogenesis of migraine [<xref rid="cns70444-bib-0006" ref-type="bibr">6</xref>, <xref rid="cns70444-bib-0007" ref-type="bibr">7</xref>]. The activation of the trigeminovascular system releases several neuropeptides and cytokines that participate in nociceptive transmission [<xref rid="cns70444-bib-0008" ref-type="bibr">8</xref>, <xref rid="cns70444-bib-0009" ref-type="bibr">9</xref>]. Calcitonin gene&#x02010;related peptide (CGRP) is a critical neuropeptide that is pathologically released from primary afferent neurons and that acts as a nociceptive mediator to accelerate inflammatory conditions [<xref rid="cns70444-bib-0010" ref-type="bibr">10</xref>, <xref rid="cns70444-bib-0011" ref-type="bibr">11</xref>, <xref rid="cns70444-bib-0012" ref-type="bibr">12</xref>, <xref rid="cns70444-bib-0013" ref-type="bibr">13</xref>]. Thus, regulation of inflammatory mediators may provide a therapeutic advantage for migraine treatment.</p><p>Endosomal toll&#x02010;like receptor 3 (TLR3) is an innate immune receptor that is widely expressed in the central nervous system (CNS) and can be activated upon inflammatory stimulation in response to pathogens [<xref rid="cns70444-bib-0014" ref-type="bibr">14</xref>]. Upon activation, TLR3 recruits the regulatory protein Toll/IL&#x02010;1 receptor domain&#x02010;containing adapter, which induces IFN&#x02010;&#x003b2; (TRIF) to participate in inflammatory activities [<xref rid="cns70444-bib-0015" ref-type="bibr">15</xref>, <xref rid="cns70444-bib-0016" ref-type="bibr">16</xref>]. Polyinosinic&#x02010;polycytidylic acid (Poly&#x02010;IC), a TLR3&#x02010;specific ligand, has shown promise in exerting neuroprotective effects, as it mitigates inflammatory actions in several diseases and conditions, including cerebral tissue injury by regulating TLR3/TRIF expression [<xref rid="cns70444-bib-0017" ref-type="bibr">17</xref>, <xref rid="cns70444-bib-0018" ref-type="bibr">18</xref>, <xref rid="cns70444-bib-0019" ref-type="bibr">19</xref>, <xref rid="cns70444-bib-0020" ref-type="bibr">20</xref>]. However, direct evidence of the role of TLR3 in migraine is still lacking. Recently, researchers reported the upregulation of TLR3 in ex&#x000a0;vivo brain slices following the induction of cortical spreading depression (CSD) [<xref rid="cns70444-bib-0021" ref-type="bibr">21</xref>], and the modulation of TLR3 by Poly&#x02010;IC effectively inhibited CSD&#x02010;induced neuroinflammation in rats, which indicates that TLR3 is a critical signaling molecule involved in CSD&#x02010;related disorders [<xref rid="cns70444-bib-0022" ref-type="bibr">22</xref>]. Since CSD is associated with several neurological disorders [<xref rid="cns70444-bib-0023" ref-type="bibr">23</xref>, <xref rid="cns70444-bib-0024" ref-type="bibr">24</xref>], the role of TLR3 and its signaling pathway in migraine still requires further clarification. Therefore, considering the potential involvement of TLR3&#x02010;mediated sterile neurogenic inflammation in the pathogenesis of migraine, we aimed to investigate the effects of Poly&#x02010;IC on migraine&#x02010;associated inflammation and the underlying mechanisms.</p><p>In this study, we established a rat model of episodic migraine to explore the beneficial effects of Poly&#x02010;IC. We subsequently conducted an in&#x02010;depth investigation of the underlying mechanisms, with a focus on inflammatory responses in&#x000a0;vitro. These findings could provide better insight into promising new strategies for the treatment of migraine.</p></sec><sec id="cns70444-sec-0006"><label>2</label><title>Methods and Materials</title><p>All experiments were conducted according to a protocol approved by the Ethics Committee of West China Hospital of Sichuan University and complied with the guidelines outlined in the National Institute of Health's Guide for the Care and Use of Laboratory Animals, as well as the Animal Research: Reporting In&#x000a0;Vivo Experiments (ARRIVE) guidelines [<xref rid="cns70444-bib-0025" ref-type="bibr">25</xref>]. The investigators who participated in the behavioral tests and endpoint data collection were blinded to the animal groups. All efforts were made to minimize suffering [<xref rid="cns70444-bib-0026" ref-type="bibr">26</xref>].</p><sec id="cns70444-sec-0007"><label>2.1</label><title>Animals</title><p>Male Sprague&#x02013;Dawley rats (weighing 200&#x02013;220&#x02009;g, purchased from Chengdu Da&#x02010;Shuo Laboratory Animal Co. Ltd.) were housed at the Laboratory Animal Center of West China Hospital of Sichuan University and bred under standard laboratory conditions, including a 12&#x02010;h light/dark cycle, a constant temperature, and unrestricted access to food and water.</p></sec><sec id="cns70444-sec-0008"><label>2.2</label><title>
<styled-content style="fixed-case" toggle="no">NTG</styled-content>&#x02010;Induced Migraine&#x02010;Like Headache Preclinical Model</title><p>The NTG&#x02010;based migraine model has greatly contributed to the identification of potential mechanisms of migraine pathogenesis and is well suited for conducting repeated controlled experiments [<xref rid="cns70444-bib-0027" ref-type="bibr">27</xref>, <xref rid="cns70444-bib-0028" ref-type="bibr">28</xref>]. In this study, NTG was purchased from Beijing Yimin Pharmaceutical Co. (Beijing, China) as a fresh dilution of 5&#x02009;mg/mL in ethanol. We then used 0.9% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) saline to further dilute NTG to a final concentration of 1&#x02009;mg/mL. Episodic migraine models were established via a single intraperitoneal injection of NTG at a dose of 10&#x02009;mg/kg [<xref rid="cns70444-bib-0029" ref-type="bibr">29</xref>]. Rats in the vehicle group were intraperitoneally injected with an equivalent volume of ethanol in saline.</p></sec><sec id="cns70444-sec-0009"><label>2.3</label><title>Administration of a <styled-content style="fixed-case" toggle="no">TLR3</styled-content> Agonist and Inhibitor</title><p>The immunopotentiator Poly&#x02010;IC, a mimic of double&#x02010;stranded viral RNA, is known to stimulate TLR3 and is considered an excellent adjuvant in different immunoregulatory models [<xref rid="cns70444-bib-0030" ref-type="bibr">30</xref>, <xref rid="cns70444-bib-0031" ref-type="bibr">31</xref>]. Poly&#x02010;IC obtained from InvivoGen (San Diego, CA, USA) was stored at &#x02212;20&#x000b0;C until use. Poly&#x02010;IC was prepared for injection by resuspending it in sterile saline, mixing it with the solution, heating it to 65&#x000b0;C&#x02013;70&#x000b0;C at a concentration of 1&#x02009;mg/mL to ensure complete solubility, and then allowing proper annealing at room temperature. 1&#x02009;h before NTG injection, the rats were intraperitoneally injected with 0.3&#x02009;mg/kg Poly&#x02010;IC (both the Poly&#x02010;IC group and the TLR3/dsRNA complex inhibitor treatment group) [<xref rid="cns70444-bib-0021" ref-type="bibr">21</xref>].</p><p>The TLR3/dsRNA complex inhibitor (Calbiochem/Merck) was shown to be a competitive inhibitor of dsRNA in binding to TLR3 with high affinity and specificity [<xref rid="cns70444-bib-0032" ref-type="bibr">32</xref>]. This inhibitor was dissolved in dimethyl sulfoxide, diluted in sterile saline as a working solution, and intraperitoneally administered 1&#x02009;h before Poly&#x02010;IC treatment at 30&#x02009;mg/kg (TLR3/dsRNA complex inhibitor treatment group) [<xref rid="cns70444-bib-0033" ref-type="bibr">33</xref>]. As a control, rats were treated with an equivalent volume of the appropriate vehicle.</p></sec><sec id="cns70444-sec-0010"><label>2.4</label><title>Behavior Test</title><sec id="cns70444-sec-0011"><label>2.4.1</label><title>Tactile Sensitivity Threshold</title><p>The mechanical sensitivity threshold of the periorbital region was evaluated with calibrated Von Frey hairs (Semmes&#x02013;Weinstein monofilaments, Stoelting Co., Wood Dale, Illinois, USA) by applying them to the midline of the forehead and near the eyes using the up&#x02013;down method [<xref rid="cns70444-bib-0034" ref-type="bibr">34</xref>, <xref rid="cns70444-bib-0035" ref-type="bibr">35</xref>]. Examples of positive responses included when animals scratched the periorbital region or withdrew their head in response to the stimulus. The tactile thresholds to the stimuli were assessed at baseline and 0.5, 1, 2, 3, and 4&#x02009;h after NTG or vehicle injection [<xref rid="cns70444-bib-0036" ref-type="bibr">36</xref>].</p></sec><sec id="cns70444-sec-0012"><label>2.4.2</label><title>Head&#x02010;Directed Wiping and Scratching</title><p>Increased grooming, especially that localized to a specific area (such as the head in migraine models), can indicate increased nociception, as previously described [<xref rid="cns70444-bib-0037" ref-type="bibr">37</xref>, <xref rid="cns70444-bib-0038" ref-type="bibr">38</xref>]. The head&#x02010;directed wiping and scratching results were recorded and calculated after injection.</p></sec><sec id="cns70444-sec-0013"><label>2.4.3</label><title>Rat Grimace Scale</title><p>Pain behavior was also assessed based on the Rat Grimace Scale (RGS), the experimental procedures of which were performed as previously described [<xref rid="cns70444-bib-0039" ref-type="bibr">39</xref>]. The changes in orbital tightening and nose&#x02010;cheek bulging in each group were recorded after injection according to the RGS.</p></sec></sec><sec id="cns70444-sec-0014"><label>2.5</label><title>Primary Neuron Cultures In&#x000a0;Vitro</title><p>The trigeminal ganglia of neonatal rats were removed and dissociated in 2&#x02009;mg/mL papain and 1&#x02009;mg/mL DNase I at 37&#x000b0;C for 30&#x02009;min for primary neuron culture. A P1000 pipette was used to triturate the digested ganglia. After centrifugation, the cells were resuspended in complete media containing DMEM/F&#x02010;12 supplemented with 10% fetal bovine serum and 1% penicillin&#x02013;streptomycin, plated on precoated 96&#x02010;, 24&#x02010;, and 6&#x02010;well plates, and cultured at 37&#x000b0;C for 4&#x02009;h after cell counting. The medium was subsequently changed to serum&#x02010;free neurobasal&#x02010;A medium containing GlutaMax, B27 supplement, and 1% penicillin&#x02013;streptomycin. The neurons were cultured for 7&#x02009;days, and on day 3, half the medium was replaced [<xref rid="cns70444-bib-0040" ref-type="bibr">40</xref>, <xref rid="cns70444-bib-0041" ref-type="bibr">41</xref>].</p><p>Capsaicin was used to mimic neurogenic inflammation, which resulted in the release of CGRP from cultured trigeminal ganglion neurons [<xref rid="cns70444-bib-0042" ref-type="bibr">42</xref>, <xref rid="cns70444-bib-0043" ref-type="bibr">43</xref>, <xref rid="cns70444-bib-0044" ref-type="bibr">44</xref>]. Briefly, before stimulation, the capsaicin (Sigma, St. Louis, MO, USA) stock solution at a concentration of 100&#x02009;mmol/L was prepared in dimethylsulfoxide (DMSO, Sigma), diluted in HEPES&#x02010;buffered saline (HBSS) and stored at 4&#x000b0;C until use. On the seventh day in&#x000a0;vitro, the neurons were washed and incubated with fresh HBSS at 37&#x000b0;C and treated with 2&#x02009;&#x003bc;M capsaicin for 1&#x02009;h [<xref rid="cns70444-bib-0042" ref-type="bibr">42</xref>]. Poly&#x02010;IC at a concentration of 25&#x02009;&#x003bc;g/mL was added 24&#x02009;h before capsaicin stimulation [<xref rid="cns70444-bib-0043" ref-type="bibr">43</xref>, <xref rid="cns70444-bib-0045" ref-type="bibr">45</xref>]. The TLR3/dsRNA complex inhibitor (100&#x02009;&#x003bc;M) was then added 1&#x02009;h before Poly&#x02010;IC preconditioning [<xref rid="cns70444-bib-0046" ref-type="bibr">46</xref>]. As a control, the cells were treated with equivalent volumes of the appropriate vehicle.</p></sec><sec id="cns70444-sec-0015"><label>2.6</label><title>Vectors and <styled-content style="fixed-case" toggle="no">shRNA</styled-content> Transduction</title><p>Rat sh<italic toggle="yes">TRIF</italic> and nontargeting control vectors (shControl) were purchased from Genechem. All the viruses express an enhanced green fluorescent protein (EGFP) under the direction of a CMV promoter, which allows the assessment of viral infection.</p><p>All the constructs were confirmed via sequencing. The sequence for the control virus was 5&#x02032;&#x02010;TTCTCCGAACGTGTCACGT&#x02010;3&#x02032;, whereas the sequences for sh<italic toggle="yes">TRIF</italic> were 5&#x02032;&#x02010;GGAACGGGCCATAGATCTTGA&#x02010;3&#x02032; (sh<italic toggle="yes">TRIF#</italic>1) and 5&#x02032;&#x02010;GAGGAAAC CCAATATCAAACT&#x02010;3&#x02032; (sh<italic toggle="yes">TRIF#</italic>2). Primary neurons were transduced with shControl or sh<italic toggle="yes">TRIF</italic> on the third day in&#x000a0;vitro for 72&#x02009;h before drug stimulation. The multiplicity of infection (MOI) was set as 8.</p></sec><sec id="cns70444-sec-0016"><label>2.7</label><title>Western Blot</title><p>In vivo, at the end of behavioral testing, trigeminal nucleus caudalis (TNC) segments, which are involved in processing pain sensation in migraine, were rapidly extracted and stored at &#x02212;80&#x000b0;C. The in&#x000a0;vitro neuron cultures were washed with ice&#x02010;cold phosphate&#x02010;buffered saline (PBS) and digested in 0.125% trypsin at 37&#x000b0;C for 3&#x02013;4&#x02009;min. The samples were homogenized in RIPA lysis buffer (CST, USA) supplemented with protease inhibitor (Beyotime, China). The protein concentration was determined using a BCA assay (Epizyme Biomedical Technology Co. Ltd., China). Protein samples were loaded in each lane and were separated via SDS&#x02010;PAGE, after which the proteins were transferred onto polyvinylidene difluoride membranes (Millipore, Temecula, CA, USA). After blocking with 5% nonfat dry milk in Tris&#x02010;buffered saline containing Tween 20 (TBST) at room temperature for 1&#x02009;h, the membranes were carefully washed and incubated with primary antibodies against CGRP (Santa Cruz, dilution: 1:50), c&#x02010;fos (Abcam, dilution: 1:500), TRIF (Proteintech, dilution: 1:500), TLR3 (Abcam, dilution: 1:500) and &#x003b2;&#x02010;actin (Proteintech, dilution: 1:800) at 4&#x000b0;C overnight. The next day, the membranes were carefully washed with TBST and incubated with horseradish peroxidase&#x02010;conjugated anti&#x02010;mouse or anti&#x02010;rabbit secondary antibodies for 1&#x02009;h at room temperature. The bands were then visualized with an enhanced chemiluminescence kit (Bio&#x02010;Rad, USA).</p></sec><sec id="cns70444-sec-0017"><label>2.8</label><title>Immunofluorescence Staining</title><p>4&#x02009;h after injection, the rats were deeply anesthetized and perfused with cold PBS (pH&#x02009;7.4) followed by 4% cold paraformaldehyde (PFA). Regions from the medulla oblongata to the cervical spinal cord (C1&#x02013;C2) were immediately isolated and postfixed at 4&#x000b0;C for 24&#x02009;h. The TNC tissue was then sequentially removed, dehydrated, embedded, and cut into 10&#x02009;&#x003bc;m&#x02010;thick transverse sections, which were obtained from representative serial paraffin&#x02010;embedded sections and subjected to immunostaining. Cells cultured in&#x000a0;vitro were washed with ice&#x02010;cold PBS and fixed in paraformaldehyde for 10&#x02009;min. After three washes in PBS, the cells were permeabilized for 15&#x02009;min with 0.3% Triton X&#x02010;100 in PBS before blocking with goat serum albumin for 1&#x02009;h at 37&#x000b0;C. Sections/cells were incubated with primary antibodies against TLR3 (Abcam, 1:500), neuronal nuclei NeuN (Abcam, 1:500), GFAP (Abcam, 1:500), Iba&#x02010;1 (Abcam, 1:500), CGRP (CST, 1:800), c&#x02010;fos (Abcam, 1:200), TRIF (Abcam, 1:500), and MAP&#x02010;2 (Invitrogen, 1:10000) overnight at 4&#x000b0;C. Samples were then incubated with fluorescent secondary antibodies for 1&#x02009;h at room temperature after extensive washing. The nuclei were counterstained with 4,6&#x02010;diamidino&#x02010;2&#x02010;phenylindole (DAPI) for 5&#x02009;min.</p></sec><sec id="cns70444-sec-0018"><label>2.9</label><title>ELISA</title><p>In accordance with the manufacturer's instructions, the levels of IL&#x02010;6 and TNF&#x02010;&#x003b1; secreted by cells in culture and by the TNC were quantified with an ELISA kit (Jiangsu Medical Industrial Co. Ltd.).</p></sec><sec id="cns70444-sec-0019"><label>2.10</label><title>Statistical Analysis</title><p>The data are presented as the mean&#x02009;&#x000b1;&#x02009;SEM. The Student's <italic toggle="yes">t</italic> test was used for two&#x02010;group comparisons. Differences in the means among multiple groups were analyzed using one&#x02010; or two&#x02010;way analysis of variance (ANOVA). Normality tests were conducted prior to performing parametric analyses. Differences were considered significant when <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05. GraphPad Prism version 9.0 was used for statistical analyses (GraphPad Software, San Diego, CA, USA).</p></sec></sec><sec sec-type="results" id="cns70444-sec-0020"><label>3</label><title>Results</title><sec id="cns70444-sec-0021"><label>3.1</label><title>Poly&#x02010;<styled-content style="fixed-case" toggle="no">IC</styled-content> Treatment Alleviates the Hyperalgesia After <styled-content style="fixed-case" toggle="no">NTG</styled-content> Injection by Increasing <styled-content style="fixed-case" toggle="no">TLR3</styled-content> Expression</title><p>The NTG&#x02010;induced migraine&#x02010;like headache preclinical model is a well&#x02010;established experimental method for inducing migraine in rodents. We first investigated migraine&#x02010;like hyperalgesia induced by NTG. As shown in the flow chart, male Sprague&#x02013;Dawley rats were intraperitoneally injected with NTG or vehicle (Figure&#x000a0;<xref rid="cns70444-fig-0001" ref-type="fig">1A</xref>). The rats exhibited characteristic migraine&#x02010;related behaviors, including frequent cephalic grooming and tightly closed eyelids. The typical behavior of frequent head scratching began 3&#x02013;5&#x02009;min after NTG administration and occurred more frequently within the first 2&#x02009;h (Figure&#x000a0;<xref rid="cns70444-fig-0001" ref-type="fig">1B,C</xref>). In line with these behaviors indicative of discomfort, we detected a decrease in the periorbital sensory withdrawal threshold after NTG delivery, which reached maximal reduction at 60&#x02013;90&#x02009;min post injection (Figure&#x000a0;<xref rid="cns70444-fig-0001" ref-type="fig">1D</xref>). In addition, rats in the NTG group exhibited more frequent head scratching (Figure&#x000a0;<xref rid="cns70444-fig-0001" ref-type="fig">1E</xref>), which indicated the successful establishment of a migraine rodent model.</p><fig position="float" fig-type="FIGURE" id="cns70444-fig-0001"><label>FIGURE 1</label><caption><p>Poly&#x02010;IC pretreatment reversed the hyperalgesia induced by NTG injection. (A) Schematic diagram of migraine induction by NTG. (B) Typical behavior of frequent head scratching after NTG injection. (C) In addition to facial signs of discomfort, rats treated with NTG were more languid and exhibited spontaneous eye closure. (D) Mechanical stimulation of the ipsilateral and contralateral orofacial sides after NTG injection measured at different time points. <italic toggle="yes">N</italic>&#x02009;=&#x02009;6/group. (E) Frequency of head scratching in 2&#x02009;h after NTG injection. <italic toggle="yes">N</italic>&#x02009;=&#x02009;6/group. (F) Schematic overview of the experimental design. (G) Several facial signs of discomfort, including partial or complete eye closure, and bulging changes in the cheeks and nose, were observed after NTG injection. Fewer facial signs of discomfort were observed after Poly&#x02010;IC treatment. (H) Mechanical stimulation of the ipsilateral and contralateral orofacial sides after Poly&#x02010;IC injection. <italic toggle="yes">N</italic>&#x02009;=&#x02009;6/group. *P represents NTG&#x02009;+&#x02009;Poly&#x02010;IC compared with NTG, and <sup>#</sup>P represents NTG&#x02009;+&#x02009;Poly&#x02010;IC compared with NTG&#x02009;+&#x02009;Poly&#x02010;IC&#x02009;+&#x02009;TLR3i. (I) Frequency of head scratching within 2&#x02009;h after Poly&#x02010;IC delivery. <italic toggle="yes">N</italic>&#x02009;=&#x02009;6/group. (J, K) TLR3 expression examined by Western blotting. The data are shown as the means &#x000b1; SEMs, ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.5, <sup>###</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="CNS-31-e70444-g001" position="anchor" id="jats-graphic-3"/></fig><p>Next, we used Poly&#x02010;IC, a double&#x02010;stranded viral RNA mimic that can stimulate TLR3, together with a specific inhibitor to investigate its effect on migraine&#x02010;like hyperalgesia (Figure&#x000a0;<xref rid="cns70444-fig-0001" ref-type="fig">1F</xref>). Impressively, Poly&#x02010;IC treatment significantly induced analgesia in a migraine rodent model. Compared with the NTG group and the Poly&#x02010;IC&#x02009;+&#x02009;TLR3 inhibitor group, rats in the Poly&#x02010;IC group presented markedly fewer head scratches, higher facial mechanical withdrawal thresholds, and fewer facial signs of discomfort (Figure&#x000a0;<xref rid="cns70444-fig-0001" ref-type="fig">1G&#x02013;I</xref>). TLR3 expression was upregulated after NTG stimulation, whereas Poly&#x02010;IC&#x02010;treated rats presented a more enhanced TLR3 expression with less migraine&#x02010;like hyperalgesia (Figure&#x000a0;<xref rid="cns70444-fig-0001" ref-type="fig">1J,K</xref>). Generally, these results indicate that NTG stimulation may increase TLR3 production during migraine attacks, whereas Poly&#x02010;IC can relieve hyperalgesia by further activating TLR3 expression.</p></sec><sec id="cns70444-sec-0022"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">NTG</styled-content> Enhances the Expression of <styled-content style="fixed-case" toggle="no">CGRP</styled-content>, c&#x02010;Fos, and Inflammatory Cytokines, While Poly&#x02010;<styled-content style="fixed-case" toggle="no">IC</styled-content> Inhibits This Effect</title><p>As described, Poly&#x02010;IC pretreatment could relieve NTG&#x02010;induced hyperalgesia by increasing TLR3 expression. Given previous reports that implicate the inflammatory response in migraine attacks, we investigated whether Poly&#x02010;IC could block the proinflammatory response in migraine. To assess this, we performed Western blotting and immunostaining for CGRP and c&#x02010;fos expression in TNC segments [<xref rid="cns70444-bib-0047" ref-type="bibr">47</xref>]. Interestingly, the expression of CGRP and c&#x02010;fos was significantly increased after NTG injection, whereas Poly&#x02010;IC treatment markedly reversed this phenomenon (Figure&#x000a0;<xref rid="cns70444-fig-0002" ref-type="fig">2A&#x02013;C</xref>). Moreover, the average optic density of CGRP&#x02010;immunoreactive fibers and the number of c&#x02010;fos&#x02010;positive cells in the superficial layers of the TNC were both typically reduced by Poly&#x02010;IC delivery (Figure&#x000a0;<xref rid="cns70444-fig-0002" ref-type="fig">2D&#x02013;H</xref>). Furthermore, NTG stimulation significantly increased the production of IL&#x02010;6 and TNF&#x02010;&#x003b1; in homogenates from the TNC, whereas Poly&#x02010;IC administration markedly reduced the levels of both cytokines (Figure&#x000a0;<xref rid="cns70444-fig-0002" ref-type="fig">2I,J</xref>). These findings reveal that Poly&#x02010;IC treatment can limit inflammation during migraine attacks by further activating TLR3 expression.</p><fig position="float" fig-type="FIGURE" id="cns70444-fig-0002"><label>FIGURE 2</label><caption><p>Poly&#x02010;IC protected against neurogenic inflammation in a rat model of migraine. (A&#x02013;C) CGRP and c&#x02010;fos expression in TNC tissue examined by Western blotting. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (D) Representative image of the TNC area subjected to CGRP immunofluorescence staining. Scale bars&#x02009;=&#x02009;200&#x02009;&#x003bc;m. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (E, F) Expression of the key neuropeptide CGRP examined by immunofluorescence. Scale bars&#x02009;=&#x02009;50&#x02009;&#x003bc;m. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (G, H) Immunofluorescence images of c&#x02010;fos expression. Scale bars&#x02009;=&#x02009;100&#x02009;&#x003bc;m. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (I, J) Levels of IL&#x02010;6 and TNF&#x02010;&#x003b1; in the TNC. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. The data are shown as the means &#x000b1; SEMs. ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="CNS-31-e70444-g005" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="cns70444-sec-0023"><label>3.3</label><title>Neurons Act as Target Cells for Poly&#x02010;<styled-content style="fixed-case" toggle="no">IC</styled-content> Treatment in Migraine</title><p>A remaining objective is to comprehensively understand the cellular and molecular mechanisms by which Poly&#x02010;IC protects against neurogenic inflammation in migraine. We performed double immunofluorescence staining to label the TLR3 protein and cell type&#x02010;specific markers in the TNC, including NeuN for neurons, Iba&#x02010;1 for microglia, and GFAP for astrocytes. Immunostaining revealed that after NTG or NTG&#x02009;+&#x02009;Poly&#x02010;IC administration, TLR3 was up&#x02010;expression than vehicle group and mainly colocalized with neurons (Figure&#x000a0;<xref rid="cns70444-fig-0003" ref-type="fig">3A</xref>) rather than microglia or astrocytes (Figure&#x000a0;<xref rid="cns70444-fig-0004" ref-type="fig">4A,B</xref>) in TNC segments. Therefore, we used primary cultured neurons to further explore the effects of TLR3 signaling in&#x000a0;vitro (Figure&#x000a0;<xref rid="cns70444-fig-0003" ref-type="fig">3B,C</xref>). Primary cultured neurons were treated with capsaicin, the active ingredient of hot chili peppers, which has been used as a chemical stimulus for cultured neurons to mimic neurogenic inflammation, as this compound increases the CGRP concentration [<xref rid="cns70444-bib-0042" ref-type="bibr">42</xref>, <xref rid="cns70444-bib-0043" ref-type="bibr">43</xref>, <xref rid="cns70444-bib-0044" ref-type="bibr">44</xref>]. Immunofluorescence staining confirmed that capsaicin stimulation prominently enhanced TLR3 expression in neurons (Figure&#x000a0;<xref rid="cns70444-fig-0003" ref-type="fig">3D,E</xref>). Moreover, ELISA revealed that the levels of the proinflammatory cytokines IL&#x02010;6 and TNF&#x02010;&#x003b1; were markedly greater in capsaicin&#x02010;treated neurons than in the neurons in the vehicle group (Figure&#x000a0;<xref rid="cns70444-fig-0003" ref-type="fig">3F,G</xref>). Overall, these results suggest that the NTG&#x02010;induced inflammatory response and Poly&#x02010;IC effects are neuron&#x02010;specific during the pathogenesis of migraine.</p><fig position="float" fig-type="FIGURE" id="cns70444-fig-0003"><label>FIGURE 3</label><caption><p>Neurons as target cells for Poly&#x02010;IC treatment in migraine. (A) Representative images showing TLR3 expression in neurons after vehicle, NTG, or NTG&#x02009;+&#x02009;Poly&#x02010;IC treatment in rats. Scale bar&#x02009;=&#x02009;50&#x02009;&#x003bc;m. (B) Schematic diagram of the experimental extraction and stimulation of neurons. (C) Representative bright field and fluorescence images of mature neurons. Scale bars&#x02009;=&#x02009;100&#x02009;&#x003bc;m. (D, E) Capsaicin stimulation enhanced TLR3 expression in primary cultured neurons. Scale bars&#x02009;=&#x02009;50&#x02009;&#x003bc;m. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (F, G) IL&#x02010;6 and TNF&#x02010;&#x003b1; protein levels in the cell supernatants of cultured neurons after stimulation with capsaicin. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. The data are shown as the means &#x000b1; SEMs. ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></caption><graphic xlink:href="CNS-31-e70444-g006" position="anchor" id="jats-graphic-7"/></fig><fig position="float" fig-type="FIGURE" id="cns70444-fig-0004"><label>FIGURE 4</label><caption><p>TLR3 expression in different cell fractions. (A, B) Representative images showing TLR3 expression in astrocytes (A) and microglia (B) after vehicle, NTG, and NTG&#x02009;+&#x02009;Poly&#x02010;IC treatment in rats. Scale bars&#x02009;=&#x02009;50&#x02009;&#x003bc;m.</p></caption><graphic xlink:href="CNS-31-e70444-g003" position="anchor" id="jats-graphic-9"/></fig></sec><sec id="cns70444-sec-0024"><label>3.4</label><title>Poly&#x02010;<styled-content style="fixed-case" toggle="no">IC</styled-content> Mitigates Inflammation by Activating the <styled-content style="fixed-case" toggle="no">TLR3</styled-content>/<styled-content style="fixed-case" toggle="no">TRIF</styled-content> Signaling Pathway</title><p>We next examined CGRP expression in&#x000a0;vitro considering its prominent role in migraine attacks. In accordance with our in&#x000a0;vivo observations, the number of CGRP&#x02010;positive neurons was significantly increased after capsaicin stimulation, whereas Poly&#x02010;IC treatment markedly suppressed CGRP expression in cultured neurons (Figure&#x000a0;<xref rid="cns70444-fig-0005" ref-type="fig">5A,B</xref>). Furthermore, Western blot analysis revealed pronounced increases in the protein levels of CGRP and c&#x02010;fos in primary cultured neurons, whereas Poly&#x02010;IC treatment mitigated this phenomenon (Figure&#x000a0;<xref rid="cns70444-fig-0005" ref-type="fig">5C&#x02013;E</xref>). In addition, exposure to capsaicin for 24&#x02009;h notably increased the levels of proinflammatory cytokines, which were reduced in the Poly&#x02010;IC group (Figure&#x000a0;<xref rid="cns70444-fig-0005" ref-type="fig">5F,G</xref>). Furthermore, we determined the involvement of TLR3 signaling in cultured neurons treated with Poly&#x02010;IC. Poly&#x02010;IC pretreatment significantly increased the production of TLR3 and its adaptor protein TRIF in cultured neurons (Figure&#x000a0;<xref rid="cns70444-fig-0005" ref-type="fig">5H&#x02013;J</xref>). These data provide evidence that Poly&#x02010;IC treatment inhibits the release of proinflammatory factors via upregulation of TLR3 and TRIF expression.</p><fig position="float" fig-type="FIGURE" id="cns70444-fig-0005"><label>FIGURE 5</label><caption><p>Poly&#x02010;IC mitigated neurogenic inflammation in&#x000a0;vitro via upregulation of TLR3 and TRIF. (A, B) Expression of CGRP in cultured neurons after stimulation with capsaicin and Poly&#x02010;IC pretreatment, as examined by immunofluorescence. Scale bars&#x02009;=&#x02009;50&#x02009;&#x003bc;m; <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (C&#x02013;E) CGRP and c&#x02010;fos expression in neurons examined by Western blotting. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (F, G) IL&#x02010;6 and TNF&#x02010;&#x003b1; protein levels in the cell supernatants of cultured neurons after treatment with Poly&#x02010;IC. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (H&#x02013;J) Expression of TLR3 and TRIF in neurons examined by Western blotting. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. The data are presented as the means &#x000b1; SEMs. ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="CNS-31-e70444-g002" position="anchor" id="jats-graphic-11"/></fig></sec><sec id="cns70444-sec-0025"><label>3.5</label><title>Poly&#x02010;<styled-content style="fixed-case" toggle="no">IC</styled-content> Protects Against Neurogenic Inflammation via <styled-content style="fixed-case" toggle="no">TLR3</styled-content>/<styled-content style="fixed-case" toggle="no">TRIF</styled-content> Signaling Pathway Activation</title><p>The above results revealed that Poly&#x02010;IC treatment activated the TLR3/TRIF signaling pathway and facilitated anti&#x02010;inflammatory effects in migraine. To comprehensively understand the functional impact of the TLR3/TRIF signaling pathway on the inflammatory response in migraine, we knocked down TRIF in primary cultured neurons via shRNA. First, Western blotting and immunofluorescence staining confirmed the efficacy of TRIF knockdown at an MOI of 8 for sh<italic toggle="yes">TRIF#</italic>1 (Figures&#x000a0;<xref rid="cns70444-fig-0006" ref-type="fig">6A,B</xref> and <xref rid="cns70444-fig-0007" ref-type="fig">7</xref>). TRIF knockdown induced an increase in CGRP and c&#x02010;fos expression in neurons (Figure&#x000a0;<xref rid="cns70444-fig-0006" ref-type="fig">6C&#x02013;E</xref>). TRIF knockdown consistently markedly increased the number of CGRP&#x02010;positive neurons even under Poly&#x02010;IC&#x02010;treated conditions (Figure&#x000a0;<xref rid="cns70444-fig-0006" ref-type="fig">6F,G</xref>), which suggests that reduced TRIF expression weakened the neuroprotective effects of TLR3 activation in migraine. Furthermore, compared with those in the shControl infection group, the levels of IL&#x02010;6 and TNF&#x02010;&#x003b1; in the cell supernatant from the Poly&#x02010;IC with TRIF&#x02010;knockdown group were increased (Figure&#x000a0;<xref rid="cns70444-fig-0006" ref-type="fig">6H,I</xref>). In summary, Poly&#x02010;IC protects against neurogenic inflammation via TLR3/TRIF signaling pathway activation in a migraine model. The mechanistic work further revealed that TRIF knockdown reduces the anti&#x02010;inflammatory capacity of Poly&#x02010;IC treatment in primary cultured neurons.</p><fig position="float" fig-type="FIGURE" id="cns70444-fig-0006"><label>FIGURE 6</label><caption><p>TRIF knockdown reduced the anti&#x02010;inflammatory capacity of TLR3 activation in primary cultured neurons. (A, B) Efficacy of TRIF knockdown (MOI of 8 for sh<italic toggle="yes">TRIF#</italic>1) examined by immunofluorescence staining. Scale bars&#x02009;=&#x02009;100&#x02009;&#x003bc;m. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (C&#x02013;E) Expression of CGRP and c&#x02010;fos after TRIF knockdown examined by Western blotting. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (F, G) Expression of CGRP in neurons after TRIF knockdown assessed by immunofluorescence staining. Scale bars&#x02009;=&#x02009;50&#x02009;&#x003bc;m. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. (H&#x02010;I) Levels of IL&#x02010;6 and TNF&#x02010;&#x003b1; secreted by cultured neurons after co&#x02010;culture with Poly&#x02010;IC and shRNA. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/group. The data are shown as the means &#x000b1; SEMs. ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="CNS-31-e70444-g004" position="anchor" id="jats-graphic-13"/></fig><fig position="float" fig-type="FIGURE" id="cns70444-fig-0007"><label>FIGURE 7</label><caption><p>Efficacy of TRIF knockdown by shRNAs in primary cultured neurons. (A, B) Expression of TRIF after shRNA infection examined by Western blotting. <italic toggle="yes">N</italic>&#x02009;=&#x02009;3/***group. <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="CNS-31-e70444-g007" position="anchor" id="jats-graphic-15"/></fig></sec></sec><sec sec-type="discussion" id="cns70444-sec-0026"><label>4</label><title>Discussion</title><p>The present study provides experimental evidence that Poly&#x02010;IC protects against neuroinflammation via the TLR3/TRIF signaling pathway in migraine. These results also confirm that TLR3 is involved in migraine attacks. Poly&#x02010;IC treatment significantly increased TLR3/TRIF expression, reduced the production of CGRP, c&#x02010;fos, and inflammatory cytokines, and alleviated NTG&#x02010;induced allodynia. TRIF knockdown weakened the anti&#x02010;inflammatory capacity of TLR3 activation induced by Poly&#x02010;IC treatment.</p><p>The activation of TLR3 can initiate immunomodulatory responses in the brain and is also involved in the pathogenesis of neuropathic pain [<xref rid="cns70444-bib-0017" ref-type="bibr">17</xref>, <xref rid="cns70444-bib-0018" ref-type="bibr">18</xref>, <xref rid="cns70444-bib-0019" ref-type="bibr">19</xref>, <xref rid="cns70444-bib-0020" ref-type="bibr">20</xref>, <xref rid="cns70444-bib-0048" ref-type="bibr">48</xref>, <xref rid="cns70444-bib-0049" ref-type="bibr">49</xref>]. To our knowledge, the role of TLR3 in migraine attacks remains unclear, which, to some extent, makes it a &#x0201c;blind spot&#x0201d; of clinical therapies. Recently, Ghaemi and colleagues reported increased expression of TLR3 in ex&#x000a0;vivo brain slices after CSD induction, indicating that TLR3 is a critical signaling molecule for CSD&#x02010;related neurological disorders [<xref rid="cns70444-bib-0022" ref-type="bibr">22</xref>]. Notably, CSD is involved in several neurological disorders, including migraine aura and stroke [<xref rid="cns70444-bib-0023" ref-type="bibr">23</xref>, <xref rid="cns70444-bib-0024" ref-type="bibr">24</xref>]. Considering this observation, we established an episodic migraine model via single injection of nitroglycerin into rats and verified that TLR3 is involved in the pathological process of migraine attack. Interestingly, inflammatory stimulation increased TLR3/TRIF production during migraine attacks, whereas further activation of TLR3/TRIF signaling by Poly&#x02010;IC relieved hyperalgesia and limited inflammation by increasing TLR3 and TRIF expression. As reported, CSD enhances TLR3 and TLR4 expression in the brain, whereas TLR3 modulation by Poly&#x02010;IC inhibits CSD&#x02010;induced neuroinflammation in the brain and spleen of rats [<xref rid="cns70444-bib-0021" ref-type="bibr">21</xref>, <xref rid="cns70444-bib-0022" ref-type="bibr">22</xref>]. Similarly, Yang et&#x000a0;al. reported that the activation of TLR3 by Poly&#x02010;IC has therapeutic effects against cerebral ischemic injury through downregulation of TLR4 signaling [<xref rid="cns70444-bib-0017" ref-type="bibr">17</xref>]. Since TLR4 is involved in migraine attacks and can be activated in trigeminal ganglion neurons in rodents when endogenous inflammation is induced [<xref rid="cns70444-bib-0050" ref-type="bibr">50</xref>], the balance of activation of these two TLR pathways may contribute to neuroinflammation in the migraine phenotype, but this remains unclear and should be verified in the future. Overall, activation of the TLR3/TRIF signaling pathway, according to our study, is a potential therapeutic strategy to ameliorate proinflammatory activity and disease severity in migraine.</p><p>As known, the nociceptive transmission originates from the activation and sensitization of first&#x02010;order trigeminal vascular neurons. Injury transmission gradually activates and sensitizes trigeminal vascular neurons in the thalamus, which subsequently transmit pain sensations to cortical areas such as the somatosensory cortex, ultimately leading to migraines. Research has focused on the potential role of glial cells in neuroinflammatory responses; however, more investigations are needed on neurons, which may provide opportunities for further exploration of the pathophysiology of migraine [<xref rid="cns70444-bib-0051" ref-type="bibr">51</xref>, <xref rid="cns70444-bib-0052" ref-type="bibr">52</xref>]. We performed double immunofluorescence staining to label the TLR3 protein and cell type&#x02010;specific markers in TNC and illustrated the pivotal role of neurons in the pathogenesis of migraine, which is in line with these previous findings.</p><p>Moreover, pretreatment with the TLR3 agonist Poly&#x02010;IC, which activates TLR3 expression in neurons, effectively alleviated pain and reduced neuronal inflammation. Neuroinflammation plays a significant role in most neurological diseases. Additionally, inflammation is generally acknowledged to be critical for migraine pathogenesis. The activation of cortical, subcortical, and brainstem regions and the subsequent release of critical neuropeptides are essential for migraine [<xref rid="cns70444-bib-0053" ref-type="bibr">53</xref>]. As a pleiotropic neuropeptide critically involved in migraine pathophysiology, CGRP induces meningeal blood vessel dilation, plasma extravasation, platelet activation, and mast cell degranulation [<xref rid="cns70444-bib-0054" ref-type="bibr">54</xref>]. When secreted at pathological concentrations, CGRP functions as a pivotal nociceptive mediator that facilitates the initiation, maintenance, and amplification of nociceptive signaling cascades in the trigeminovascular system [<xref rid="cns70444-bib-0055" ref-type="bibr">55</xref>, <xref rid="cns70444-bib-0056" ref-type="bibr">56</xref>]. Therefore, these neurotransmitters and inflammatory factors have become therapeutic targets for the treatment of migraine [<xref rid="cns70444-bib-0054" ref-type="bibr">54</xref>]. Recent studies have shown that the application of the TLR3 agonist Poly&#x02010;IC protects against cerebral ischemic injury by suppressing damaging inflammatory responses and enhancing endogenous neuroprotection [<xref rid="cns70444-bib-0017" ref-type="bibr">17</xref>, <xref rid="cns70444-bib-0018" ref-type="bibr">18</xref>, <xref rid="cns70444-bib-0019" ref-type="bibr">19</xref>, <xref rid="cns70444-bib-0020" ref-type="bibr">20</xref>]. Other researchers have reported that the activation of TLR3 expression reduces TNF&#x02010;&#x003b1; levels to attenuate LPS&#x02010;induced liver injury [<xref rid="cns70444-bib-0057" ref-type="bibr">57</xref>]. Notably, the current literature provides little evidence of the role of the TLR3&#x02010;mediated signaling pathway in migraine pathogenesis. Our investigation provides evidence that Poly&#x02010;IC administration induces TLR3 activation, which mechanistically suppresses CGRP secretion and downregulates key proinflammatory mediators (e.g., IL&#x02010;6 and TNF&#x02010;&#x003b1;) in both animal models and primary neuron cultures. These observations suggest that TLR3 may be a potential therapeutic target for migraine treatment.</p><p>A thorough understanding of the mechanisms by which Poly&#x02010;IC&#x02010;induced TLR3 activation preserves homeostasis in migraine is still needed. Notably, TRIF&#x02010;dependent TLR3 signaling is critical for cytokine production in neurons, and neuronal TLR3 activation likely uses TRIF to activate gene expression in innate immunity [<xref rid="cns70444-bib-0058" ref-type="bibr">58</xref>]. As reported, Poly&#x02010;IC treatment enhances TRIF protein expression, reduces neuronal apoptosis, and inhibits proinflammatory cytokine production following ischemic injury [<xref rid="cns70444-bib-0017" ref-type="bibr">17</xref>, <xref rid="cns70444-bib-0018" ref-type="bibr">18</xref>, <xref rid="cns70444-bib-0019" ref-type="bibr">19</xref>, <xref rid="cns70444-bib-0020" ref-type="bibr">20</xref>]. Preconditioning with Poly&#x02010;IC activates the TLR3 signaling pathway via TRIF, thereby inducing neuroprotection in an experimental stroke model [<xref rid="cns70444-bib-0018" ref-type="bibr">18</xref>]. Moreover, previous studies have shown that innate immune signaling via toll&#x02010;like receptor signaling is responsible for persistent pain [<xref rid="cns70444-bib-0059" ref-type="bibr">59</xref>]. In this study, we observed that the activation of the TLR3/TRIF pathway by Poly&#x02010;IC treatment can inhibit inflammatory responses and reduce neurogenic inflammation injury in migraine. These findings suggest that TLR3/TRIF signaling plays pivotal roles in inflammatory processing and nociceptive signaling.</p><p>Our study has some limitations. This study focused on neuroinflammatory conditions and the subsequent release of proinflammatory cytokines that contribute to the initiation of facilitated pain states, which cannot explain the full mechanism of migraine. We believe the results may underlie the migraine phenotype and introduce a novel drug target with therapeutic potential for migraine attacks. In addition, since the mechanistic work was performed in&#x000a0;vitro in our study, more evidence of the involvement of the TLR3/TRIF signaling pathway in migraine attack is needed. Additionally, for the sake of comparability with previous studies, to avoid the influence of hormonal fluctuations on experimental outcomes, we elected to use only male rats to establish an episodic migraine model. The sex differences involved in the pathophysiological mechanisms of migraine therefore require further exploration.</p></sec><sec sec-type="conclusions" id="cns70444-sec-0027"><label>5</label><title>Conclusions</title><p>These findings highlight the critical role of the TLR3/TRIF signaling pathway in migraine, which is associated with neuroprotective and anti&#x02010;inflammatory effects after Poly&#x02010;IC delivery. As shown, Poly&#x02010;IC treatment increased TLR3/TRIF expression, suppressed the production of CGRP, c&#x02010;fos, and proinflammatory cytokines, and alleviated migraine&#x02010;like hyperalgesia. Therefore, the activation of TLR3/TRIF by Poly&#x02010;IC is a promising therapeutic strategy that could be used to counteract migraine attacks.</p></sec><sec id="cns70444-sec-0028"><title>Author Contributions</title><p>Y.H. and M.M. designed the study, conducted experiments, analyzed the data, and drafted the manuscript. C.L., Y.Z., and Y.L. provided key experimental techniques, helped perform experiments, and analyzed the data. N.C. contributed to the study design. J.F. and L.H. designed the study, supervised the experimental work, and revised this manuscript. All authors read and approved the final manuscript.</p></sec><sec id="cns70444-sec-0030"><title>Ethics Statement</title><p>The study protocol was approved by the Local Ethics Committee of West China Hospital, Sichuan University.</p></sec><sec sec-type="COI-statement" id="cns70444-sec-0031"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cns70444-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1.
</p></caption><media xlink:href="CNS-31-e70444-s001.pdf"/></supplementary-material></sec></body><back><ack id="cns70444-sec-0029"><title>Acknowledgments</title><p>We are sincerely grateful to the staff of Core Facilities of West China hospital (TianFu) for technical assistance. We thank Dr. Yilin Liu at Sun Yat&#x02010;Sen University for comments on the manuscript.</p></ack><sec sec-type="data-availability" id="cns70444-sec-0033"><title>Data Availability Statement</title><p>The data supporting this study's findings are available from the corresponding author upon request.</p></sec><ref-list content-type="cited-references" id="cns70444-bibl-0001"><title>References</title><ref id="cns70444-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cns70444-cit-0001">
<string-name>
<given-names>M.</given-names>
<surname>Ashina</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Katsarava</surname>
</string-name>, <string-name>
<given-names>T. P.</given-names>
<surname>Do</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Migraine: Epidemiology and Systems of Care</article-title>,&#x0201d; <source>Lancet</source>
<volume>397</volume>, no. <issue>10283</issue> (<year>2021</year>): <fpage>1485</fpage>&#x02013;<lpage>1495</lpage>.<pub-id pub-id-type="pmid">33773613</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cns70444-cit-0002">
<collab collab-type="authors">GBD</collab>
, &#x0201c;<article-title>Neurology Collaborators (2019) Global, Regional, and National Burden of Neurological Disorders, 1990&#x02013;2016: A Systematic Analysis for the Global Burden of Disease Study 2016</article-title>,&#x0201d; <source>Lancet Neurology</source>
<volume>18</volume>, no. <issue>5</issue> (<year>2016</year>): <fpage>459</fpage>&#x02013;<lpage>480</lpage>.</mixed-citation></ref><ref id="cns70444-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cns70444-cit-0003">
<string-name>
<given-names>A.</given-names>
<surname>Gonzalez&#x02010;Hernandez</surname>
</string-name>, <string-name>
<given-names>B. A.</given-names>
<surname>Marichal&#x02010;Cancino</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>MaassenVanDenBrink</surname>
</string-name>, and <string-name>
<given-names>C. M.</given-names>
<surname>Villal&#x000f3;n</surname>
</string-name>, &#x0201c;<article-title>Side Effects Associated With Current and Prospective Antimigraine Pharmacotherapies</article-title>,&#x0201d; <source>Expert Opinion on Drug Metabolism &#x00026; Toxicology</source>
<volume>14</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>25</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">29226741</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cns70444-cit-0004">
<string-name>
<given-names>R. B.</given-names>
<surname>Lipton</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Fanning</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Serrano</surname>
</string-name>, <string-name>
<given-names>M. L.</given-names>
<surname>Reed</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Cady</surname>
</string-name>, and <string-name>
<given-names>D. C.</given-names>
<surname>Buse</surname>
</string-name>, &#x0201c;<article-title>Ineffective Acute Treatment of Episodic Migraine Is Associated With New&#x02010;Onset Chronic Migraine</article-title>,&#x0201d; <source>Neurology</source>
<volume>84</volume>, no. <issue>7</issue> (<year>2015</year>): <fpage>688</fpage>&#x02013;<lpage>695</lpage>.<pub-id pub-id-type="pmid">25609757</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cns70444-cit-0005">
<string-name>
<given-names>A. P.</given-names>
<surname>Andreou</surname>
</string-name> and <string-name>
<given-names>L.</given-names>
<surname>Edvinsson</surname>
</string-name>, &#x0201c;<article-title>Mechanisms of Migraine as a Chronic Evolutive Condition</article-title>,&#x0201d; <source>Journal of Headache and Pain</source>
<volume>20</volume> (<year>2019</year>): <fpage>117</fpage>.<pub-id pub-id-type="pmid">31870279</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cns70444-cit-0006">
<string-name>
<given-names>J.</given-names>
<surname>Khan</surname>
</string-name>, <string-name>
<given-names>L. I. A.</given-names>
<surname>Asoom</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Sunni</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Rafique</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Latif</surname>
</string-name>, and <string-name>
<given-names>S. A.</given-names>
<surname>Saif</surname>
</string-name>, &#x0201c;<article-title>Genetics, Pathophysiology, Diagnosis, Treatment, Management, and Prevention of Migraine</article-title>,&#x0201d; <source>Biomedicine &#x00026; Pharmacotherapy</source>
<volume>139</volume> (<year>2021</year>): <elocation-id>111557</elocation-id>.<pub-id pub-id-type="pmid">34243621</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cns70444-cit-0007">
<string-name>
<given-names>P.</given-names>
<surname>Durham</surname>
</string-name> and <string-name>
<given-names>S.</given-names>
<surname>Papapetropoulos</surname>
</string-name>, &#x0201c;<article-title>Biomarkers Associated With Migraine and Their Potential Role in Migraine Management</article-title>,&#x0201d; <source>Headache</source>
<volume>53</volume>, no. <issue>8</issue> (<year>2013</year>): <fpage>1262</fpage>&#x02013;<lpage>1277</lpage>.<pub-id pub-id-type="pmid">23848170</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cns70444-cit-0008">
<string-name>
<given-names>R.</given-names>
<surname>Ramachandran</surname>
</string-name>, &#x0201c;<article-title>Neurogenic Inflammation and Its Role in Migraine</article-title>,&#x0201d; <source>Seminars in Immunopathology</source>
<volume>40</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>301</fpage>&#x02013;<lpage>314</lpage>.<pub-id pub-id-type="pmid">29568973</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cns70444-cit-0009">
<string-name>
<given-names>S.</given-names>
<surname>Iyengar</surname>
</string-name>, <string-name>
<given-names>K. W.</given-names>
<surname>Johnson</surname>
</string-name>, <string-name>
<given-names>M. H.</given-names>
<surname>Ossipov</surname>
</string-name>, and <string-name>
<given-names>S. K.</given-names>
<surname>Aurora</surname>
</string-name>, &#x0201c;<article-title>CGRP and the Trigeminal System in Migraine</article-title>,&#x0201d; <source>Headache</source>
<volume>59</volume>, no. <issue>5</issue> (<year>2019</year>): <fpage>659</fpage>&#x02013;<lpage>681</lpage>.<pub-id pub-id-type="pmid">30982963</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cns70444-cit-0010">
<string-name>
<given-names>K.</given-names>
<surname>Warfvinge</surname>
</string-name> and <string-name>
<given-names>L.</given-names>
<surname>Edvinsson</surname>
</string-name>, &#x0201c;<article-title>Distribution of CGRP and CGRP Receptor Components in the Rat Brain</article-title>,&#x0201d; <source>Cephalalgia</source>
<volume>39</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>342</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="pmid">28856910</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cns70444-cit-0011">
<string-name>
<given-names>F. G.</given-names>
<surname>Perini</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Galloni</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Pignatelli</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Plasma Cytokine Levels in Migraineurs and Controls</article-title>,&#x0201d; <source>Headache</source>
<volume>45</volume>, no. <issue>7</issue> (<year>2010</year>): <fpage>926</fpage>&#x02013;<lpage>931</lpage>.</mixed-citation></ref><ref id="cns70444-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cns70444-cit-0012">
<string-name>
<given-names>K. A.</given-names>
<surname>Haanes</surname>
</string-name> and <string-name>
<given-names>L.</given-names>
<surname>Edvinsson</surname>
</string-name>, &#x0201c;<article-title>Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets</article-title>,&#x0201d; <source>CNS Drugs</source>
<volume>33</volume>, no. <issue>6</issue> (<year>2019</year>): <fpage>525</fpage>&#x02013;<lpage>537</lpage>.<pub-id pub-id-type="pmid">30989485</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cns70444-cit-0013">
<string-name>
<given-names>A.</given-names>
<surname>Alpuente</surname>
</string-name>, <string-name>
<given-names>V. J.</given-names>
<surname>Gallardo</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Asskour</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Caronna</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Torres&#x02010;Ferrus</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Pozo&#x02010;Rosich</surname>
</string-name>, &#x0201c;<article-title>Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine</article-title>,&#x0201d; <source>Annals of Neurology</source>
<volume>92</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>846</fpage>&#x02013;<lpage>859</lpage>.<pub-id pub-id-type="pmid">36054144</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cns70444-cit-0014">
<string-name>
<given-names>M.</given-names>
<surname>Bsibsi</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Ravid</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Gveric</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>van Noort</surname>
</string-name>, &#x0201c;<article-title>Broad Expression of Toll&#x02010;Like Receptors in the Human Central Nervous System</article-title>,&#x0201d; <source>Journal of Neuropathology and Experimental Neurology</source>
<volume>61</volume>, no. <issue>11</issue> (<year>2002</year>): <fpage>1013</fpage>&#x02013;<lpage>1021</lpage>.<pub-id pub-id-type="pmid">12430718</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cns70444-cit-0015">
<string-name>
<given-names>M.</given-names>
<surname>Bsibsi</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Bajramovic</surname>
</string-name>, <string-name>
<given-names>M. H.</given-names>
<surname>Vogt</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Microtubule Regulator Stathmin Is an Endogenous Protein Agonist for TLR3</article-title>,&#x0201d; <source>Journal of Immunology</source>
<volume>184</volume>, no. <issue>12</issue> (<year>2010</year>): <fpage>6929</fpage>&#x02013;<lpage>6937</lpage>.</mixed-citation></ref><ref id="cns70444-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cns70444-cit-0016">
<string-name>
<given-names>W. B.</given-names>
<surname>Veldhuis</surname>
</string-name>, <string-name>
<given-names>J. W.</given-names>
<surname>Derksen</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Floris</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Interferon&#x02010;Beta Blocks Infiltration of Inflammatory Cells and Reduces Infarct Volume After Ischemic Stroke in the Rat</article-title>,&#x0201d; <source>Journal of Cerebral Blood Flow and Metabolism</source>
<volume>23</volume>, no. <issue>9</issue> (<year>2003</year>): <fpage>1029</fpage>&#x02013;<lpage>1039</lpage>.<pub-id pub-id-type="pmid">12973019</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cns70444-cit-0017">
<string-name>
<given-names>P. F.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>X. Y.</given-names>
<surname>Xiong</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>Y. C.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Duan</surname>
</string-name>, and <string-name>
<given-names>Q. W.</given-names>
<surname>Yang</surname>
</string-name>, &#x0201c;<article-title>Function and Mechanism of Toll&#x02010;Like Receptors in Cerebral Ischemic Tolerance: From Preconditioning to Treatment</article-title>,&#x0201d; <source>Journal of Neuroinflammation</source>
<volume>12</volume> (<year>2015</year>): <fpage>80</fpage>.<pub-id pub-id-type="pmid">25928750</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cns70444-cit-0018">
<string-name>
<given-names>L. N.</given-names>
<surname>Pan</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>X. L.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>L. J.</given-names>
<surname>Guo</surname>
</string-name>, and <string-name>
<given-names>Q.</given-names>
<surname>Lu</surname>
</string-name>, &#x0201c;<article-title>Toll&#x02010;Like Receptor 3 Agonist Poly I:C Protects Against Simulated Cerebral Ischemia In&#x000a0;Vitro and In&#x000a0;Vivo</article-title>,&#x0201d; <source>Acta Pharmacologica Sinica</source>
<volume>33</volume>, no. <issue>10</issue> (<year>2012</year>): <fpage>1246</fpage>&#x02013;<lpage>1253</lpage>.<pub-id pub-id-type="pmid">22983393</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cns70444-cit-0019">
<string-name>
<given-names>L. N.</given-names>
<surname>Pan</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Astrocytic Toll&#x02010;Like Receptor 3 Is Associated With Ischemic Preconditioning&#x02010;Induced Protection Against Brain Ischemia in Rodents</article-title>,&#x0201d; <source>PLoS One</source>
<volume>9</volume>, no. <issue>6</issue> (<year>2014</year>): <elocation-id>e99526</elocation-id>.<pub-id pub-id-type="pmid">24914679</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cns70444-cit-0020">
<string-name>
<given-names>A. E.</given-names>
<surname>Packard</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Hedges</surname>
</string-name>, <string-name>
<given-names>F. R.</given-names>
<surname>Bahjat</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Poly&#x02010;IC Preconditioning Protects Against Cerebral and Renal Ischemia&#x02010;Reperfusion Injury</article-title>,&#x0201d; <source>Journal of Cerebral Blood Flow and Metabolism</source>
<volume>32</volume>, no. <issue>2</issue> (<year>2012</year>): <fpage>242</fpage>&#x02013;<lpage>247</lpage>.<pub-id pub-id-type="pmid">22086194</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cns70444-cit-0021">
<string-name>
<given-names>A.</given-names>
<surname>Ghaemi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sajadian</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Khodaie</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Immunomodulatory Effect of Toll&#x02010;Like Receptor&#x02010;3 Ligand Poly I:C on Cortical Spreading Depression</article-title>,&#x0201d; <source>Molecular Neurobiology</source>
<volume>53</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>143</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">25416860</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cns70444-cit-0022">
<string-name>
<given-names>A.</given-names>
<surname>Ghaemi</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Alizadeh</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Babaei</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Astrocyte&#x02010;Mediated Inflammation in Cortical Spreading Depression</article-title>,&#x0201d; <source>Cephalalgia</source>
<volume>38</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>626</fpage>&#x02013;<lpage>638</lpage>.<pub-id pub-id-type="pmid">28372497</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cns70444-cit-0023">
<string-name>
<given-names>A.</given-names>
<surname>Gorji</surname>
</string-name>, &#x0201c;<article-title>Spreading Depression: A Review of the Clinical Relevance</article-title>,&#x0201d; <source>Brain Research Reviews</source>
<volume>38</volume>, no. <issue>1&#x02013;2</issue> (<year>2001</year>): <fpage>33</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">11750926</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cns70444-cit-0024">
<string-name>
<given-names>J. P.</given-names>
<surname>Dreier</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Major</surname>
</string-name>, <string-name>
<given-names>H. W.</given-names>
<surname>Pannek</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Spreading Convulsions, Spreading Depolarization and Epileptogenesis in Human Cerebral Cortex</article-title>,&#x0201d; <source>Brain</source>
<volume>135</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>259</fpage>&#x02013;<lpage>275</lpage>.<pub-id pub-id-type="pmid">22120143</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cns70444-cit-0025">
<string-name>
<given-names>N.</given-names>
<surname>Percie du Sert</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Hurst</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ahluwalia</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The ARRIVE Guidelines 2. 0: Updated Guidelines for Reporting Animal Research</article-title>,&#x0201d; <source>Journal of Cerebral Blood Flow and Metabolism</source>
<volume>40</volume>, no. <issue>9</issue> (<year>2020</year>): <fpage>1769</fpage>&#x02013;<lpage>1777</lpage>.<pub-id pub-id-type="pmid">32663096</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cns70444-cit-0026">
<string-name>
<given-names>M.</given-names>
<surname>Zimmermann</surname>
</string-name>, &#x0201c;<article-title>Ethical Guidelines for Investigations of Experimental Pain in Conscious Animals</article-title>,&#x0201d; <source>Pain</source>
<volume>16</volume>, no. <issue>2</issue> (<year>1983</year>): <fpage>109</fpage>&#x02013;<lpage>110</lpage>.<pub-id pub-id-type="pmid">6877845</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cns70444-cit-0027">
<string-name>
<given-names>A. M.</given-names>
<surname>Harriott</surname>
</string-name>, <string-name>
<given-names>L. C.</given-names>
<surname>Strother</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Vila&#x02010;Pueyo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Animal Models of Migraine and Experimental Techniques Used to Examine Trigeminal Sensory Processing</article-title>,&#x0201d; <source>Journal of Headache and Pain</source>
<volume>20</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>91</fpage>.<pub-id pub-id-type="pmid">31464579</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cns70444-cit-0028">
<string-name>
<given-names>P.</given-names>
<surname>Sureda&#x02010;Gibert</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Romero&#x02010;Reyes</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Akerman</surname>
</string-name>, &#x0201c;<article-title>Nitroglycerin as a Model of Migraine: Clinical and Preclinical Review</article-title>,&#x0201d; <source>Neurobiology of Pain</source>
<volume>12</volume> (<year>2022</year>): <elocation-id>100105</elocation-id>.<pub-id pub-id-type="pmid">36974065</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cns70444-cit-0029">
<string-name>
<given-names>B.</given-names>
<surname>Alpay</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Cimen</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Akaydin</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Onat</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Bolay</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Sara</surname>
</string-name>, &#x0201c;<article-title>Extrasynaptic &#x003b4;GABAA Receptors Mediate Resistance to Migraine&#x02010;Like Phenotype in Rats</article-title>,&#x0201d; <source>Journal of Headache and Pain</source>
<volume>25</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>75</fpage>.<pub-id pub-id-type="pmid">38724972</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cns70444-cit-0030">
<string-name>
<given-names>M.</given-names>
<surname>Matsumoto</surname>
</string-name> and <string-name>
<given-names>T.</given-names>
<surname>Seya</surname>
</string-name>, &#x0201c;<article-title>TLR3: Interferon Induction by Double&#x02010;Stranded RNA Including Poly (I:C)</article-title>,&#x0201d; <source>Advanced Drug Delivery Reviews</source>
<volume>60</volume> (<year>2008</year>): <fpage>805</fpage>&#x02013;<lpage>812</lpage>.<pub-id pub-id-type="pmid">18262679</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cns70444-cit-0031">
<string-name>
<given-names>M.</given-names>
<surname>Bsibsi</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Persoon&#x02010;Deen</surname>
</string-name>, <string-name>
<given-names>R. W.</given-names>
<surname>Verwer</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Meeuwsen</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Ravid</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Van Noort</surname>
</string-name>, &#x0201c;<article-title>Toll&#x02010;Like Receptor 3 on Adult Human Astrocytes Triggers Production of Neuroprotective Mediators</article-title>,&#x0201d; <source>Glia</source>
<volume>53</volume>, no. <issue>7</issue> (<year>2006</year>): <fpage>688</fpage>&#x02013;<lpage>695</lpage>.<pub-id pub-id-type="pmid">16482523</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cns70444-cit-0032">
<string-name>
<given-names>K.</given-names>
<surname>Cheng</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Yin</surname>
</string-name>, &#x0201c;<article-title>Small&#x02010;Molecule Inhibitors of the TLR3/dsRNA Complex</article-title>,&#x0201d; <source>Journal of the American Chemical Society</source>
<volume>133</volume>, no. <issue>11</issue> (<year>2011</year>): <fpage>3764</fpage>&#x02013;<lpage>3767</lpage>.<pub-id pub-id-type="pmid">21355588</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cns70444-cit-0033">
<string-name>
<given-names>C.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Li</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Extracellular RNAs&#x02010;TLR3 Signaling Contributes to Cognitive Decline in a Mouse Model of Postoperative Cognitive Dysfunction</article-title>,&#x0201d; <source>Brain, Behavior, and Immunity</source>
<volume>80</volume> (<year>2019</year>): <fpage>439</fpage>&#x02013;<lpage>451</lpage>.<pub-id pub-id-type="pmid">30980952</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cns70444-cit-0034">
<string-name>
<given-names>T.</given-names>
<surname>Aczel</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Kun</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Szoke</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Transcriptional Alterations in the Trigeminal Ganglia, Nucleus and Peripheral Blood Mononuclear Cells in a Rat Orofacial Pain Model</article-title>,&#x0201d; <source>Frontiers in Molecular Neuroscience</source>
<volume>11</volume> (<year>2018</year>): <fpage>219</fpage>.<pub-id pub-id-type="pmid">29997476</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cns70444-cit-0035">
<string-name>
<given-names>M.</given-names>
<surname>De Felice</surname>
</string-name>, <string-name>
<given-names>M. H.</given-names>
<surname>Ossipov</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Triptan&#x02010;Induced Latent Sensitization: A Possible Basis for Medication Overuse Headache</article-title>,&#x0201d; <source>Annals of Neurology</source>
<volume>67</volume>, no. <issue>3</issue> (<year>2010</year>): <fpage>325</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">20373344</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cns70444-cit-0036">
<string-name>
<given-names>W.</given-names>
<surname>Di</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Shi</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Lv</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Activation of the Nuclear Factor E2&#x02010;Related Factor 2/Anitioxidant Response Element Alleviates the Nitroglycerin&#x02010;Induced Hyperalgesia in Rats</article-title>,&#x0201d; <source>Journal of Headache and Pain</source>
<volume>17</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>99</fpage>.<pub-id pub-id-type="pmid">27778243</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cns70444-cit-0037">
<string-name>
<given-names>C.</given-names>
<surname>Tassorelli</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Greco</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Sandrini</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Sandrini</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Nappi</surname>
</string-name>, &#x0201c;<article-title>Nitroglycerin Induces Hyperalgesia in Rats&#x02014;A Time&#x02010;Course Study</article-title>,&#x0201d; <source>European Journal of Pharmacology</source>
<volume>464</volume>, no. <issue>2&#x02013;3</issue> (<year>2003</year>): <fpage>203</fpage>&#x02013;<lpage>210</lpage>.</mixed-citation></ref><ref id="cns70444-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cns70444-cit-0038">
<string-name>
<given-names>X. F.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>W. J.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>C. L.</given-names>
<surname>Dong</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Analgesia Effect of Baicalein Against NTG&#x02010;Induced Migraine in Rats</article-title>,&#x0201d; <source>Biomedicine &#x00026; Pharmacotherapy</source>
<volume>90</volume> (<year>2017</year>): <fpage>116</fpage>&#x02013;<lpage>121</lpage>.<pub-id pub-id-type="pmid">28343071</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cns70444-cit-0039">
<string-name>
<given-names>S. G.</given-names>
<surname>Sotocinal</surname>
</string-name>, <string-name>
<given-names>R. E.</given-names>
<surname>Sorge</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Zaloum</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Rat Grimace Scale: A Partially Automated Method for Quantifying Pain in the Laboratory Rat via Facial Expressions</article-title>,&#x0201d; <source>Molecular Pain</source>
<volume>7</volume> (<year>2011</year>): <fpage>55</fpage>.<pub-id pub-id-type="pmid">21801409</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cns70444-cit-0040">
<string-name>
<given-names>A. P.</given-names>
<surname>Andreou</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Leese</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Greco</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Double&#x02010;Binding Botulinum Molecule With Reduced Muscle Paralysis: Evaluation in In&#x000a0;Vitro and In&#x000a0;Vivo Models of Migraine</article-title>,&#x0201d; <source>Neurotherapeutics</source>
<volume>18</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>556</fpage>&#x02013;<lpage>568</lpage>, <pub-id pub-id-type="doi">10.1007/s13311-020-00967-7</pub-id>.<pub-id pub-id-type="pmid">33205382</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cns70444-cit-0041">
<string-name>
<given-names>J.</given-names>
<surname>Meng</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Lawrence</surname>
</string-name>, and <string-name>
<given-names>J. O.</given-names>
<surname>Dolly</surname>
</string-name>, &#x0201c;<article-title>Synaptobrevin I Mediates Exocytosis of CGRP From Sensory Neurons and Inhibition by Botulinum Toxins Reflects Their Anti&#x02010;Nociceptive Potential</article-title>,&#x0201d; <source>Journal of Cell Science</source>
<volume>120</volume>, no. <issue>16</issue> (<year>2007</year>): <fpage>2864</fpage>&#x02013;<lpage>2874</lpage>, <pub-id pub-id-type="doi">10.1242/jcs.012211</pub-id>.<pub-id pub-id-type="pmid">17666428</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cns70444-cit-0042">
<string-name>
<given-names>C.</given-names>
<surname>Vause</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Bowen</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Spierings</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Durham</surname>
</string-name>, &#x0201c;<article-title>Effect of Carbon Dioxide on Calcitonin Gene&#x02010;Related Peptide Secretion From Trigeminal Neurons</article-title>,&#x0201d; <source>Headache</source>
<volume>47</volume>, no. <issue>10</issue> (<year>2007</year>): <fpage>1385</fpage>&#x02013;<lpage>1397</lpage>.<pub-id pub-id-type="pmid">18052948</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cns70444-cit-0043">
<string-name>
<given-names>L.</given-names>
<surname>Ritchie</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Tate</surname>
</string-name>, <string-name>
<given-names>L. H.</given-names>
<surname>Chamberlain</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Toll&#x02010;Like Receptor 3 Activation Impairs Excitability and Synaptic Activity via TRIF Signalling in Immature Rat and Human Neurons</article-title>,&#x0201d; <source>Neuropharmacology</source>
<volume>135</volume> (<year>2018</year>): <fpage>1</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">29505789</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="cns70444-cit-0044">
<string-name>
<given-names>P. L.</given-names>
<surname>Durham</surname>
</string-name> and <string-name>
<given-names>C. G.</given-names>
<surname>Masterson</surname>
</string-name>, &#x0201c;<article-title>Two Mechanisms Involved in Trigeminal CGRP Release: Implications for Migraine Treatment</article-title>,&#x0201d; <source>Headache</source>
<volume>53</volume>, no. <issue>1</issue> (<year>2013</year>): <fpage>67</fpage>&#x02013;<lpage>80</lpage>, <pub-id pub-id-type="doi">10.1111/j.1526-4610.2012.02262.x</pub-id>.<pub-id pub-id-type="pmid">23095108</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="cns70444-cit-0045">
<string-name>
<given-names>B.</given-names>
<surname>Zimmer</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Ewaleifoh</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Harschnitz</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Human iPSC&#x02010;Derived Trigeminal Neurons Lack Constitutive TLR3&#x02010;Dependent Immunity That Protects Cortical Neurons From HSV&#x02010;1 Infection</article-title>,&#x0201d; <source>Proceedings of the National Academy of Sciences of the United States of America</source>
<volume>115</volume>, no. <issue>37</issue> (<year>2018</year>): <fpage>E8775</fpage>&#x02013;<lpage>E8782</lpage>, <pub-id pub-id-type="doi">10.1073/pnas.1809853115</pub-id>.<pub-id pub-id-type="pmid">30154162</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="cns70444-cit-0046">
<string-name>
<given-names>Y. L.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>M. T.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>P. S.</given-names>
<surname>Sung</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Endosomal TLR3 Co&#x02010;Receptor CLEC18A Enhances Host Immune Response to Viral Infection</article-title>,&#x0201d; <source>Communications Biology</source>
<volume>4</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>229</fpage>, <pub-id pub-id-type="doi">10.1038/s42003-021-01745-7</pub-id>.<pub-id pub-id-type="pmid">33603190</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="cns70444-cit-0047">
<string-name>
<given-names>S.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Ren</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Zhu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A c&#x02010;Fos Activation Map in Nitroglycerin /Levcromakalim&#x02010;Induced Models of Migraine</article-title>,&#x0201d; <source>Journal of Headache and Pain</source>
<volume>23</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>128</fpage>, <pub-id pub-id-type="doi">10.1186/s10194-022-01496-8</pub-id>.<pub-id pub-id-type="pmid">36180824</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="cns70444-cit-0048">
<string-name>
<given-names>I. L.</given-names>
<surname>Werkman</surname>
</string-name>, <string-name>
<given-names>M. L.</given-names>
<surname>Dubbelaar</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>van der Vlies</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>de Boer&#x02010;Bergsma</surname>
</string-name>, <string-name>
<given-names>B. J. L.</given-names>
<surname>Eggen</surname>
</string-name>, and <string-name>
<given-names>W.</given-names>
<surname>Baron</surname>
</string-name>, &#x0201c;<article-title>Transcriptional Heterogeneity Between Primary Adult Grey and White Matter Astrocytes Underlie Differences in Modulation of In&#x000a0;Vitro Myelination</article-title>,&#x0201d; <source>Journal of Neuroinflammation</source>
<volume>17</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>373</fpage>, <pub-id pub-id-type="doi">10.1186/s12974-020-02045-3</pub-id>.<pub-id pub-id-type="pmid">33308248</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="cns70444-cit-0049">
<string-name>
<given-names>W.</given-names>
<surname>Chen</surname>
</string-name> and <string-name>
<given-names>Z.</given-names>
<surname>Lu</surname>
</string-name>, &#x0201c;<article-title>Upregulated TLR3 Promotes Neuropathic Pain by Regulating Utophagy in Rat With L5 Spinal Nerve Ligation Model</article-title>,&#x0201d; <source>Neurochemical Research</source>
<volume>42</volume>, no. <issue>2</issue> (<year>2017</year>): <fpage>634</fpage>&#x02013;<lpage>643</lpage>.<pub-id pub-id-type="pmid">28000161</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="cns70444-cit-0050">
<string-name>
<given-names>M.</given-names>
<surname>Su</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Ran</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>He</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Inhibition of Toll&#x02010;Like Receptor 4 Alleviates Hyperalgesia Induced by Acute Dural Inflammation in Experimental Migraine</article-title>,&#x0201d; <source>Molecular Pain</source>
<volume>14</volume> (<year>2018</year>): <elocation-id>1744806918754612</elocation-id>, <pub-id pub-id-type="doi">10.1177/1744806918754612</pub-id>.<pub-id pub-id-type="pmid">29310498</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="cns70444-cit-0051">
<string-name>
<given-names>W.</given-names>
<surname>He</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Zhou</surname>
</string-name>, &#x0201c;<article-title>The Status of Knowledge on Migraines: The Role of Microglia</article-title>,&#x0201d; <source>Journal of Neuroimmunology</source>
<volume>381</volume> (<year>2023</year>): <elocation-id>578118</elocation-id>.<pub-id pub-id-type="pmid">37295033</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="cns70444-cit-0052">
<string-name>
<given-names>F.</given-names>
<surname>De Logu</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Nassini</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Hegron</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Schwann Cell Endosome CGRP Signals Elicit Periorbital Mechanical Allodynia in Mice</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>13</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>646</fpage>, <pub-id pub-id-type="doi">10.1038/s41467-022-28204-z</pub-id>.</mixed-citation></ref><ref id="cns70444-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="cns70444-cit-0053">
<string-name>
<given-names>K.</given-names>
<surname>Messlinger</surname>
</string-name>, &#x0201c;<article-title>Migraine: Where and How Does the Pain Originate?</article-title>,&#x0201d; <source>Experimental Brain Research</source>
<volume>196</volume>, no. <issue>1</issue> (<year>2009</year>): <fpage>179</fpage>&#x02013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">19288089</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="cns70444-cit-0054">
<string-name>
<given-names>R.</given-names>
<surname>Messina</surname>
</string-name> and <string-name>
<given-names>P. J.</given-names>
<surname>Goadsby</surname>
</string-name>, &#x0201c;<article-title>CGRP&#x02014;A Target for Acute Therapy in Migraine: Clinical Data</article-title>,&#x0201d; <source>Cephalalgia</source>
<volume>39</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>420</fpage>&#x02013;<lpage>427</lpage>.<pub-id pub-id-type="pmid">29616830</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="cns70444-cit-0055">
<string-name>
<given-names>L.</given-names>
<surname>Edvinsson</surname>
</string-name>, <string-name>
<given-names>K. A.</given-names>
<surname>Haanes</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Warfvinge</surname>
</string-name>, and <string-name>
<given-names>D. N.</given-names>
<surname>Krause</surname>
</string-name>, &#x0201c;<article-title>CGRP as the Target of New Migraine Therapies&#x02010;Successful Translation From Bench to Clinic Nature Reviews</article-title>,&#x0201d; <source>Neurology</source>
<volume>14</volume>, no. <issue>6</issue> (<year>2018</year>): <fpage>338</fpage>&#x02013;<lpage>350</lpage>.<pub-id pub-id-type="pmid">29691490</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="cns70444-cit-0056">
<string-name>
<given-names>K.</given-names>
<surname>Messlinger</surname>
</string-name>, &#x0201c;<article-title>The Big CGRP Flood&#x02010;Sources, Sinks and Signaling Sites in the Trigeminovascular System</article-title>,&#x0201d; <source>Journal of Headache and Pain</source>
<volume>19</volume> (<year>2018</year>): <fpage>22</fpage>.<pub-id pub-id-type="pmid">29532195</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="cns70444-cit-0057">
<string-name>
<given-names>W.</given-names>
<surname>Jiang</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Wei</surname>
</string-name>, and <string-name>
<given-names>Z.</given-names>
<surname>Tian</surname>
</string-name>, &#x0201c;<article-title>Toll&#x02010;Like Receptor 3 Ligand Attenuates LPS&#x02010;Induced Liver Injury by Down&#x02010;Regulation of Toll&#x02010;Like Receptor 4 Expression on Macrophages</article-title>,&#x0201d; <source>Proceedings of the National Academy of Sciences of the United States of America</source>
<volume>102</volume>, no. <issue>47</issue> (<year>2005</year>): <fpage>17077</fpage>&#x02013;<lpage>17082</lpage>.<pub-id pub-id-type="pmid">16287979</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="cns70444-cit-0058">
<string-name>
<given-names>M.</given-names>
<surname>Yamamoto</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Sato</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Hemmi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Role of Adaptor TRIF in the MyD88&#x02010;Independent Toll&#x02010;Like Receptor Signaling Pathway</article-title>,&#x0201d; <source>Science</source>
<volume>301</volume>, no. <issue>5633</issue> (<year>2003</year>): <fpage>640</fpage>&#x02013;<lpage>643</lpage>, <pub-id pub-id-type="doi">10.1126/science.1087262</pub-id>.<pub-id pub-id-type="pmid">12855817</pub-id>
</mixed-citation></ref><ref id="cns70444-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="cns70444-cit-0059">
<string-name>
<given-names>M. J.</given-names>
<surname>Lacagnina</surname>
</string-name>, <string-name>
<given-names>L. R.</given-names>
<surname>Watkins</surname>
</string-name>, and <string-name>
<given-names>P. M.</given-names>
<surname>Grace</surname>
</string-name>, &#x0201c;<article-title>Toll&#x02010;Like Receptors and Their Role in Persistent Pain</article-title>,&#x0201d; <source>Pharmacology &#x00026; Therapeutics</source>
<volume>184</volume>, no. <issue>145</issue> (<year>2018</year>): <fpage>58</fpage>.</mixed-citation></ref></ref-list></back></article>